Prokidney to host virtual kol event to discuss current treatment landscape of chronic kidney disease caused by diabetes and data from phase 2 rmcl-002 clinical trial on may 28, 2024

Winston-salem, n.c., may 21, 2024 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), will host a virtual kol event on tuesday, may 28, 2024 at 8:00 am et, featuring steven g. coca, do, ms (icahn school of medicine at mount sinai) and arnold l. silva, md, phd (university of arizona) who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe ckd caused by diabetes as well as the importance of preserving kidney function in this patient population. to register, click here .
prok Ratings Summary
prok Quant Ranking